A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6950 participants.
Also called NCT07761117
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,950 participants
- Sponsor
- Registry
-
NCT07761117 -
2026-526304-79-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Mexico, Netherlands, Poland, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Arab Emirates, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07761117. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2029-09-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
- Acronym
- Elevate-HF
- Condition
- Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07761117- Content hash
78cd5621e82f2ff33aa2c9a0eb9cb8d915467094a7492539be48f39b48929f68